Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC).

被引：0
|
作者：
Kozioff, M.
Sledge, G. W.
Benedetti, F. M.
Starr, A.
Wallace, J. A.
Stuart, M. J.
Gruver, D.
Miller, K.
机构：
[1] Ingalls Hosp, Harvey, IL USA
[2] Univ Chicago, Harvey, IL USA
[3] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[4] Genon Corp, Menlo Pk, CA USA
[5] Monroe Med Assoc, Harvey, IL USA
[6] Univ Chicago, St Marys Hosp, Monroe Med Assoc, Chicago, IL 60637 USA
[7] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2598
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Biomarkers as potential predictors of response to treatment with motesanib or bevacizumab in combination with paclitaxel (P) in patients (pts) with locally recurrent or advanced metastatic breast cancer (MBC)
    Patterson, S. D.
    Davis, M. T.
    Mackey, J. R.
    Martin, M.
    Hei, Y.
    Bass, M. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): A phase I/II study
    Fornier, M. N.
    Morris, P. G.
    Abbruzzi, A.
    D'Andrea, G.
    Gilewski, T.
    Bromberg, J.
    Dang, C. T.
    Dickler, M. N.
    Norton, L.
    Hudis, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] A PHASE I-II STUDY OF DASATINIB (D) IN COMBINATION WITH WEEKLY (W) PACLITAXEL (P) FOR PATIENTS (PTS) WITH METASTATIC BREAST CARCINOMA (MBC)
    Fornier, M. N.
    Morris, P. G.
    Abbruzzi, A.
    D'Andrea, G.
    Gilewski, T.
    Lake, D.
    Norton, L.
    Chang, J.
    Hudis, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 110 - 110
  • [4] A Phase I-II Trial of Dasatinib (D) in Combination with Weekly (w) Paclitaxel (P) for Patients (Pts) with Metastatic Breast Carcinoma (MBC)
    Morris, P. G.
    Abbruzzi, A.
    D'Andrea, G.
    Gilewski, T.
    Lake, D.
    Bromberg, J.
    Dang, C.
    Dickler, M.
    Modi, S.
    Seidman, A. D.
    Sklarin, N.
    Chang, J.
    Patil, S.
    Norton, L.
    Hudis, C. A.
    Fornier, M. N.
    CANCER RESEARCH, 2010, 70
  • [5] Phase I study of paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, B.
    Neumann, H.
    Roy, R.
    Kummer, G.
    Strumberg, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Phase I study with paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, B.
    Neumann, H.
    Roy, R.
    Heuer, V
    Kummer, G.
    Strumberg, D.
    ONKOLOGIE, 2011, 34 : 110 - 110
  • [7] A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study
    Ralph Salloum
    Trent R. Hummel
    Shiva Senthil Kumar
    Kathleen Dorris
    Shaoyu Li
    Tong Lin
    Vinay M. Daryani
    Clinton F. Stewart
    Lili Miles
    Tina Young Poussaint
    Charles Stevenson
    Stewart Goldman
    Girish Dhall
    Roger Packer
    Paul Fisher
    Ian F. Pollack
    Maryam Fouladi
    James Boyett
    Rachid Drissi
    Journal of Neuro-Oncology, 2016, 129 : 443 - 451
  • [8] Quality of life (QoL) in patients (pts) treated with bevacizumab (BV) and taxane therapy for locally recurrent (LR) or metastatic breast cancer (mBC)
    Greil, R.
    Im, Y. H.
    Pienkowski, T.
    Wardley, A.
    Awada, A.
    Ciruelos, E.
    Freitas-Junior, R.
    Fumoleau, P.
    Miles, D. W.
    EJC SUPPLEMENTS, 2009, 7 (02): : 266 - 266
  • [9] A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study
    Salloum, Ralph
    Hummel, Trent R.
    Kumar, Shiva Senthil
    Dorris, Kathleen
    Li, Shaoyu
    Lin, Tong
    Daryani, Vinay M.
    Stewart, Clinton F.
    Miles, Lili
    Poussaint, Tina Young
    Stevenson, Charles
    Goldman, Stewart
    Dhall, Girish
    Packer, Roger
    Fisher, Paul
    Pollack, Ian F.
    Fouladi, Maryam
    Boyett, James
    Drissi, Rachid
    JOURNAL OF NEURO-ONCOLOGY, 2016, 129 (03) : 443 - 451
  • [10] Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC).
    Traina, T. A.
    Rugo, H.
    Caravelli, J.
    Yeh, B.
    Panageas, K.
    Bruckner, J.
    Norton, L.
    Park, J.
    Hudis, C.
    Dickler, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 133S - 133S
12345